Practice Essentials in Pancreatic Cancer

Treating Advanced Metastatic Pancreatic Cancer: Current Challenges and Future Opportunities
Treating Advanced Metastatic Pancreatic Cancer: Current Challenges and Future Opportunities
CME, CPE
Vincent J. Picozzi, Jr., MD, MMM
Release Date: January 23, 2019
Expiration Date: January 23, 2020

Pancreatic cancer is the hardest to treat out of any major cancer, both biologically and clinically, which is why clinicians face so many unique challenges. However, there are efforts being taken to improve patient outcomes. In this activity, Dr. Vincent Picozzi from the Virginia Mason Medical Center will outline the current pipeline across advanced metastatic pancreatic cancer treatment. He will also summarize recent findings regarding risk factors, biology, and multimodality treatment.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
Your Patient is Diagnosed with Metastatic Pancreatic Cancer: Do You Know the Best Treatment Options?
Your Patient is Diagnosed with Metastatic Pancreatic Cancer: Do You Know the Best Treatment Options?
CME, CPE
Tanios Bekaii-Saab, MD, FACP
Release Date: August 16, 2018
Expiration Date: August 16, 2019

Pancreatic cancer ranks as the third leading cause of cancer-related mortality in the United States, and experts are predicting that it will rise to second place in the next decade. The management of patients with metastatic pancreatic cancer continues to be challenging for clinicians, and few treatment options are available. However, new active areas of research are investigating first- and second-line therapies that may soon expand the treatment armamentarium. In this activity, Dr. Tanios Bekaii-Saab explores two of the latest front-line options being explored in advanced metastatic pancreatic cancer. He also discusses how front-line therapy choices could impact treatment options for second-line therapy.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
Updates in Pancreatic Cancer: Advances in Treatment and Research
Updates in Pancreatic Cancer: Advances in Treatment and Research
CME, CPE
Alok A. Khorana, MD
Release Date: September 11, 2017
Expiration Date: September 11, 2018

To learn more about combination chemotherapy regimens for resected pancreatic cancer, the potential future role of immunotherapy in advanced pancreatic cancer, clinical trial updates in the neoadjuvant setting, and new guideline updates from the American Society of Clinical Oncology, view this engaging video to stay up to date with recent progress in this disease.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
 Drug Sequencing Strategies in Metastatic Pancreatic Cancer
Drug Sequencing Strategies in Metastatic Pancreatic Cancer
CME, CPE
Bert H. O’Neil, MD
Release Date: April 17, 2017
Expiration Date: April 17, 2018

In this activity, participants will be provided with an overview of treatment paradigms for first- and second-line metastatic pancreatic cancer, and insight into different drug sequencing strategies tailored to individual patient- and disease-related factors, such as age, comorbidities, performance status, and response/toxicity to prior therapy.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
The Future of Personalized Medicine in Pancreatic Cancer
The Future of Personalized Medicine in Pancreatic Cancer
CME, CPE
Eileen M. O'Reilly, MD
Release Date: April 25, 2016
Expiration Date: April 25, 2017
Over the past several years, a number of biomarkers have been investigated in pancreatic adenocarcinoma, but to date, none have been validated for routine clinical decision-making. In this activity, Dr. Eileen O’Reilly presents a state-of-the-state synopsis of our current understanding of potential diagnostic biomarkers, briefly reviewing those that have been investigated and failed to achieve success, as well as those that are showing promise for use in the clinical setting in the near future.

To download the accompanying e-Transcript for reference purposes only click here.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
View Only, CE ExpiredView Only, No Credit
 
Establishing a Palliative Care Plan for Patients with Pancreatic Cancer
Establishing a Palliative Care Plan for Patients with Pancreatic Cancer
CME, CPE
David Hui, MD
Release Date: October 26, 2016
Expiration Date: October 26, 2017

Studies indicate that when patients with pancreatic cancer are treated with therapeutic strategies that include effective palliative care, outcomes are improved. This activity will address the goals and rationale of palliative care in pancreatic cancer, and provide practical guidance for developing effective palliative care strategies for every pancreatic cancer patient.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
View Only, CE ExpiredView Only, No Credit
 
Advanced Metastatic Pancreatic Cancer: A Practical Guide to Tailoring First-line Therapy
Advanced Metastatic Pancreatic Cancer: A Practical Guide to Tailoring First-line Therapy
CME, CPE
Philip A. Philip, MD, PhD, FRCP
Release Date: February 19, 2016
Expiration Date: February 19, 2017
This activity will address therapies beyond gemcitabine monotherapy for pancreatic cancer, including other recommended options for first-line treatment such as FOLFIRINOX and gemcitabine combinations with nab-paclitaxel, erlotinib, and other agents.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
View Only, CE ExpiredView Only, No Credit
 

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of PartnersinPancreaticCancer.com.

©2020 MediCom Worldwide, Inc. All rights reserved